⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006789 | 1.00 | — | — | |
| SCHEMBL5015220 | 1.00 | — | — | |
| SCHEMBL15168974 | 1.00 | — | — | |
| SCHEMBL199118 | 0.95 | THRB (0.41) | — | |
| SCHEMBL198579 | 0.95 | THRB (0.41) | — | |
| SCHEMBL1564813 | 0.95 | THRB (0.41) | — | |
| SCHEMBL199064 | 0.95 | THRB (0.41) | — | |
| SCHEMBL199052 | 0.95 | THRB (0.41) | — | |
| SCHEMBL6866130 | 0.85 | — | — | |
| SCHEMBL13515822 | 0.76 | ADH1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118354791-A | Peptides inhibiting viral SARS-COV-2 infection leading to new coronapneumonic disease | 威斯康星校友研究基金会 | 2024-07-16 | — | — | CN | claimed |
| CN-117343556-A | Bio-based compound modified cracking carbon black and application thereof in tire preparation | 中策橡胶集团股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-117247608-A | Tire pad rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117247639-A | Tire inner liner rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| WO-2023069728-A1 | PEPTIDES THAT INHIBIT INFECTION BY SARS-COV-2, THE VIRUS THAT CAUSES COVID-19 DISEASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-04-27 | — | — | WO | claimed |
| CN-111511757-A | Polymeric agonists of mu opioid receptors | 细胞凝胶制药有限责任公司 | 2020-08-07 | — | — | CN | claimed |
| US-10723779-B2 | Alpha/beta-polypeptide analogs of glucagon-like peptide 1 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-07-28 | — | — | US | claimed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-9738697-B2 | Alpha/beta-polypeptide analogs of glucagon-like peptide-1 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| CN-102066416-A | Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RES & DEV GMBH | 2011-05-18 | — | — | CN | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| WO-2010043444-A2 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND/OR PREVENTION OF ISCHEMIA/REPERFUSION INJURY AND THE SEQUELS THEREOF | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4153310-B1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 PHARMA GMBH (AT) | 2026-02-18 | — | — | EP | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12370245-B2 | ALK polypeptides and methods of use thereof | Elicio Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250177503-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | disclosed |
| CN-119451972-A | Modified sophorolipids with enhanced defoaming properties | 轨迹方案IPCO有限责任公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-12-24 | — | — | US | disclosed |
| CN-119053211-A | Preparation method and application of ultra-small grain full-coverage infrared perovskite film | 河南省科学院物理研究所 | 2024-11-29 | — | — | CN | disclosed |
| CN-118879592-A | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-11-01 | — | — | CN | disclosed |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240294962-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE | 2024-09-05 | — | — | US | disclosed |
| EP-4419140-A1 | PEPTIDES THAT INHIBIT INFECTION BY SARS-COV-2, THE VIRUS THAT CAUSES COVID-19 DISEASE | Wisconsin Alumni Research Foundation (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-12037403-B2 | Compositions and methods for treating cancer with anti-CD123 immunotherapy | LENTIGEN TECHNOLOGY, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118354791-A | Peptides inhibiting viral SARS-COV-2 infection leading to new coronapneumonic disease | 威斯康星校友研究基金会 | 2024-07-16 | — | — | CN | disclosed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024118635-A2 | THERMOSTABLE BINDING SCAFFOLDS | NECTAGEN, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11957787-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240117363-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| US-20240075142-A1 | Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy | LENTIGEN TECHNOLOGY, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-117343556-A | Bio-based compound modified cracking carbon black and application thereof in tire preparation | 中策橡胶集团股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4297796-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117247639-A | Tire inner liner rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-117247608-A | Tire pad rubber composition containing bio-based modified cracking carbon black, mixing method and tire | 中策橡胶集团股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-117202938-A | Variant Fc domains and uses thereof | 奇达拉治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023192975-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230302108-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | F4 PHARMA GMBH (AT) | 2023-09-21 | — | — | US | disclosed |
| US-11761007-B2 | Production of unnatural nucleotides using a CRISPR/Cas9 system | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023164476-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4228707-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | University of Connecticut (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023150684-A2 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| CN-116457034-A | Nanomaterial and method of use thereof | 康涅狄格大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-116445398-A | WNT composition and purification method | 小利兰斯坦福大学托管委员会 | 2023-07-18 | — | — | CN | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4192512-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2023069728-A1 | PEPTIDES THAT INHIBIT INFECTION BY SARS-COV-2, THE VIRUS THAT CAUSES COVID-19 DISEASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11623002-B2 | ALK polypeptides and methods of use thereof | Elicio Therapeutics, Inc. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230106577-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4153310-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 Pharma GmbH (AT) | 2023-03-29 | — | — | EP | disclosed |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230082611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20230001010-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-05 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-11510992-B1 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-11492385-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME LLC (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220325238-A1 | WNT COMPOSITIONS AND METHODS FOR SERUM-FREE SYNTHESIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-13 | — | — | US | disclosed |
| EP-4045050-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | The Scripps Research Institute (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045043-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | Vividion Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220257787-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-4041247-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220243244-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2022-08-04 | — | — | US | disclosed |
| US-20220228148-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| US-20220226434-A1 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-21 | — | — | US | disclosed |
| EP-4028392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4025256-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4017529-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220175943-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3999110-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220133893-A1 | Therapeutic Nanomaterials | UNIVERSITY OF CONNECTICUT | 2022-05-05 | — | — | US | disclosed |
| WO-2022081721-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3982994-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3982993-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983543-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3976635-A1 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3938051-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMAN-LA ROCHE, INC. | 2022-01-06 | — | — | US | disclosed |
| EP-3125906-B1 | PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF | UNIV CALIFORNIA (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210371463-A1 | Modified Netrin-1 Peptides and Compositions for Cardioprotection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2021-11-25 | — | — | US | disclosed |
| WO-2021233971-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-25 | — | — | WO | disclosed |
| EP-3912679-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-24 | — | — | EP | disclosed |
| US-20210332083-A1 | Netrin-1 Compounds and Compositions Thereof for Treating Pulmonary Hypertension | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| EP-3893895-A1 | NETRIN-1 COMPOUNDS AND COMPOSITIONS THEREOF FOR TREATING PULMONARY HYPERTENSION | The Regents of University of California (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893894-A1 | MODIFIED NETRIN-1 PEPTIDES AND COMPOSITIONS FOR CARDIOPROTECTION | The Regents of University of California (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210255193-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2021-08-19 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| EP-3846846-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | Cidara Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210179684-A1 | NEUROTROPHIN MUTANTS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SARAGOVI HORACIO URI (CA) | 2021-06-17 | — | — | US | disclosed |
| US-20210130479-A1 | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-05-06 | — | — | US | disclosed |
| WO-2021081515-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076703-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021072167-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021067313-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10967042-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021035177-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-10905739-B2 | Peptidomimetic macrocycles and formulations thereof | AILERON THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2021016082-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-28 | — | — | WO | disclosed |
| EP-3769776-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210007987-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| US-20200405834-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. | 2020-12-31 | — | — | US | disclosed |
| US-20200399588-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | ANKASA REGENERATIVE THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200392196-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020252262-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252396-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392550-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE | 2020-12-17 | — | — | US | disclosed |
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3110828-B1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | UNIV SZEGEDI (HU) | 2020-12-09 | — | — | EP | disclosed |
| US-10859585-B2 | Lipid probes and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-08 | — | — | US | disclosed |
| WO-2020243060-A1 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200377877-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10845367-B2 | Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents | Abilita Bio, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3732187-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | The Scripps Research Institute (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10813884-B2 | WNT compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200318122-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2020-10-08 | — | — | US | disclosed |
| US-10793615-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2020190742-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200292555-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-09-17 | — | — | US | disclosed |
| US-20200289609-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200270570-A1 | WNT COMPOSITIONS AND METHODS FOR SERUM-FREE SYNTHESIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| CN-111511757-A | Polymeric agonists of mu opioid receptors | 细胞凝胶制药有限责任公司 | 2020-08-07 | — | — | CN | disclosed |
| US-10723779-B2 | Alpha/beta-polypeptide analogs of glucagon-like peptide 1 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-07-28 | — | — | US | disclosed |
| CN-111386282-A | T cell receptor recognizing mutated p53 | 美国卫生和人力服务部 | 2020-07-07 | — | — | CN | disclosed |
| WO-2020123578-A1 | NETRIN-1 COMPOUNDS AND COMPOSITIONS THEREOF FOR TREATING PULMONARY HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123576-A1 | MODIFIED NETRIN-1 PEPTIDES AND COMPOSITIONS FOR CARDIOPROTECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3661475-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | Ankasa Regenerative Therapeutics, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-2822572-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020112868-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-10670605-B2 | Cysteine reactive probes and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3642630-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | The Scripps Research Institute (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20200085908-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
| EP-3621633-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200040048-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10550163-B2 | Peptide fragments of netrin-1 and compositions and methods thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2020023502-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190343914-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190338008-A1 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME LLC | 2019-11-07 | — | — | US | disclosed |
| US-20190293666-A1 | LIPID PROBES AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190269753-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190256559-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190216893-A1 | COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE | 2019-07-18 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190137496-A1 | METHODS AND PLATFORM FOR PREPARING MULTISPANNING MEMBRANE PROTEINS | Abilita Bio, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-10253067-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3452516-A1 | METHODS AND PLATFORM FOR PREPARING MULTISPANNING MEMBRANE PROTEINS | Abilita Bio, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2019028186-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | ANKASA REGENERATIVE THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3432904-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-10168342-B2 | Lipid probes and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180371044-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2018237334-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180371021-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180372751-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-12-27 | — | — | US | disclosed |
| EP-3407907-A1 | WNT COMPOSITIONS AND METHODS FOR SERUM-FREE SYNTHESIS | The Board of Trustees of the Leland Stanford Junior University (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3407871-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Vedantra Pharmaceuticals Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180340009-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| WO-2018208954-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| WO-2018187574-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| US-20180273587-A1 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS INC (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3377521-A2 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018165575-A2 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| EP-3365686-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | The Scripps Research Institute (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10059741-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2018140799-A2 | NEUROTROPHIN MUTANTS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | HORACIO URI SARAGOVI (CA) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140792-A2 | NEUROTROPHIN MUTANTS FOR TREATING HEARING LOSS AND OTHER OTIC DISORDERS | OTONOMY, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-3347372-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | Aileron Therapeutics, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| WO-2018128826-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| EP-3344275-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9937126-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3294318-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3274712-A1 | LIPID PROBES AND USES THEREOF | The Scripps Research Institute (US) | 2018-01-31 | — | — | EP | disclosed |
| WO-2018018010-A1 | FGF MUTANTS AND USES THEREOF | METACRINE, INC. (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018006063-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| US-20170369871-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. | 2017-12-28 | — | — | US | disclosed |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| WO-2017218949-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2017205786-A1 | CELL PERMEABLE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017192743-A1 | METHODS AND PLATFORM FOR PREPARING MULTISPANNING MEMBRANE PROTEINS | Abilita Bio, Inc. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170320928-A1 | ALPHA/BETA-POLYPEPTIDE ANALOGS OF GLUCAGON-LIKE PEPTIDE 1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-09 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170281720-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2017-10-05 | — | — | US | disclosed |
| WO-2017165299-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-9738697-B2 | Alpha/beta-polypeptide analogs of glucagon-like peptide-1 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017132494-A1 | WNT COMPOSITIONS AND METHODS FOR SERUM-FREE SYNTHESIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132555-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | VEDANTRA PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-3197478-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197477-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | Aileron Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170210780-A1 | Peptide Fragments of Netrin-1 and Compositions and Methods Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| WO-2017106767-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017074798-A2 | LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017070611-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170115303-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017040990-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-3125906-A1 | PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF | The Regents of the University of California (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2017004548-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-3110828-A1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | Szegedi Tudományegyetem (HU) | 2017-01-04 | — | — | EP | disclosed |
| US-9522947-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9505804-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160333049-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160310424-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| WO-2016160544-A1 | LIPID PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016154058-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160282369-A1 | LIPID PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-09-29 | — | — | US | disclosed |
| EP-3052121-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2016115168-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20160193283-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160137710-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| EP-3016674-A2 | ALPHA-/BETA-POLYPEPTIDE ANALOGS OF PARATHYROID HORMONE (PTH) AND METHOD OF USING SAME | Wisconsin Alumni Research Foundation (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20160101145-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2016-04-14 | — | — | US | disclosed |
| WO-2016049355-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049359-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160052970-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160045572-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2968469-A2 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | Longevity Biotech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015157508-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015153402-A1 | PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015128687-A1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | Szegedi Tudományegyetem (HU) | 2015-09-03 | — | — | WO | disclosed |
| US-9096684-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2015051122-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| EP-2822572-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2819688-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2014209893-A2 | ALPHA-/BETA-POLYPEPTIDE ANALOGS OF PARATHYROID HORMONE (PTH) AND METHOD OF USING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209886-A1 | ALPHA/BETA-POLYPEPTIDE ANALOGS OF GLUCAGON-LIKE PEPTID-1 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378382-A1 | ALPHA-/BETA-POLYPEPTIDE ANALOGS OF PARATHYROID HORMONE (PTH) AND METHOD OF USING SAME | MASSACHUSETTS GENERAL HOSPITAL (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378375-A1 | ALPHA/BETA-POLYPEPTIDE ANALOGS OF GLUCAGON-LIKE PEPTIDE 1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-25 | — | — | US | disclosed |
| CN-104066435-A | Proteolytically resistant hydrogen bond surrogate helices | UNIV NEW YORK | 2014-09-24 | — | — | CN | disclosed |
| WO-2014145718-A2 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014138429-A2 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-2768518-A1 | PEPTIDOMIMETIC MACROCYLES | Aileron Therapeutics, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013123267-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123266-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8513381-B2 | Melanocortin analogs with antimicrobial activity | FONDAZIONE IRCCS CA' GRANDA-OSPEDALE MAGGIORE POLICLINICO (IT) | 2013-08-20 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013059525-A1 | PEPTIDOMIMETIC MACROCYLES | AILERON THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013021344-A1 | IMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | LUPIN LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-2379587-B1 | MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY | FOND IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO (IT) | 2012-11-28 | — | — | EP | disclosed |
| US-20120015873-A1 | MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY | FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO (IT) | 2012-01-19 | — | — | US | disclosed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | disclosed |
| CN-102245625-A | Method of making biologically active alpha-beta peptides | WISCONSIN ALUMNI RES FOUND | 2011-11-16 | — | — | CN | disclosed |
| EP-2379587-A1 | MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY | Fondazione IRCCS "CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO" (IT) | 2011-10-26 | — | — | EP | disclosed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | disclosed |
| CN-102066416-A | Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RES & DEV GMBH | 2011-05-18 | — | — | CN | disclosed |
| CN-101954247-A | The film that comprises the amino acid movable carrier | GEN ELECTRIC | 2011-01-26 | — | — | CN | disclosed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | disclosed |
| US-20100218681-A1 | MEMBRANES COMPRISING AMINO ACID MOBILE CARRIERS | GENERAL ELECTRIC COMPANY (US) | 2010-09-02 | — | — | US | disclosed |
| EP-2223964-A1 | Membranes comprising amino acid mobile carriers | General Electric Company (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010081492-A1 | MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY | FONDAZIONE OSPEDALE MAGGIORE POLICLINICO MANGIAGALLI REGINA ELENA - MILANO (IT) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010043444-A2 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND/OR PREVENTION OF ISCHEMIA/REPERFUSION INJURY AND THE SEQUELS THEREOF | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | disclosed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | disclosed |
| CN-101443325-A | 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-27 | — | — | CN | disclosed |
| EP-0879244-B1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE AND VACCINES | UNIV MELBOURNE (AU) | 2009-02-11 | — | — | EP | disclosed |
| US-20060159707-A1 | Lawsonia derived gene and related FlgE polypeptides, peptides and proteins and their uses | PANACCIO MICHAEL | 2006-07-20 | — | — | US | disclosed |
| US-7052697-B1 | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses | AGRICULTURE VICTORIA SERVICES PTY LTD (AU) | 2006-05-30 | — | — | US | disclosed |
| US-7029683-B1 | Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses | PFIZER PRODUCTS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060018920-A1 | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses | HASSE DETLEF | 2006-01-26 | — | — | US | disclosed |
| US-20050232939-A1 | Novel therapeutic compositions for treating infection by Lawsonia spp. | ROSEY EVERETT L | 2005-10-20 | — | — | US | disclosed |
| EP-1332154-A4 | NOVEL THERAPEUTIC COMPOSITIONS FOR TREATING INFECTION BY LAWSONIA SPP | AGRICULTURE VICTORIA SERV PTY (AU) | 2005-05-11 | — | — | EP | disclosed |
| US-6846487-B2 | Therapeutic compositions for treating infection by Lawsonia spp. | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20050009151-A1 | Methods for the stereospecific and enantiomeric enrichment of beta-amino acids | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-20030157120-A1 | Lawsonia derived gene and related flge polypeptides, peptides and proteins and their uses | AGRICULTURE VICTORIA SERVICES PTY LTD. (AU) | 2003-08-21 | — | — | US | disclosed |
| EP-1332154-A1 | NOVEL THERAPEUTIC COMPOSITIONS FOR TREATING INFECTION BY LAWSONIA SPP | Agriculture Victoria Services Pty Ltd (AU) | 2003-08-06 | — | — | EP | disclosed |
| US-20030103999-A1 | Novel therapeutic compositions for treating infection by Lawsonia spp. | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1183268-A4 | LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | AUSTRALIAN PORK LTD (AU) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002038594-A9 | NOVEL THERAPEUTIC COMPOSITIONS FOR TREATING INFECTION BY LAWSONIA SPP | AGRICULTURE VICTORIA SERV PTY (AU) | 2002-11-07 | — | — | WO | disclosed |
| EP-1177213-A4 | LAWSONIA DERIVED GENE AND RELATED HEMOLYSIN POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | PFIZER PROD INC (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1181315-A4 | LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | PFIZER PROD INC (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002038594-A1 | NOVEL THERAPEUTIC COMPOSITIONS FOR TREATING INFECTION BY LAWSONIA SPP | AGRICULTURE VICTORIA SERVICES PTY. LTD. (AU) | 2002-05-16 | — | — | WO | disclosed |
| EP-1051624-A4 | HIGH DENSITY ARRAYS FOR PROTEOME ANALYSIS AND METHODS AND COMPOSITIONS THEREFOR | GLAUCUS PROTEOMICS B V (NL) | 2002-05-02 | — | — | EP | disclosed |
| EP-1183268-A1 | LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | Australian Pork Limited (AU) | 2002-03-06 | — | — | EP | disclosed |
| EP-1181315-A1 | LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1177213-A1 | LAWSONIA DERIVED GENE AND RELATED HEMOLYSIN POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0879244-A4 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | UNIV MELBOURNE (AU) | 2001-12-05 | — | — | EP | disclosed |
| CN-1312817-A | Dolastatin 15 derivatives | BASF AG (DE) | 2001-09-12 | — | — | CN | disclosed |
| US-20010018422-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT | 2001-08-30 | — | — | US | disclosed |
| EP-1093460-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-25 | — | — | EP | disclosed |
| US-6171589-B1 | ARE USEFUL IN PROTECTING INDIVIDUALS AGAINST INFECTIONS BY SPECIES OF THE GENUS MYCOPLAMA. | THE UNIVERSITY OF MELBOURNE (AU) | 2001-01-09 | — | — | US | disclosed |
| WO-2000069904-A1 | LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | PFIZER PRODUCTS INC (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069906-A1 | LAWSONIA DERIVED GENE AND RELATED HEMOLYSIN POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | PFIZER PRODUCTS INC (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069905-A1 | LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | AUSTRALIAN PORK LIMITED (AU) | 2000-11-23 | — | — | WO | disclosed |
| EP-1051624-A1 | HIGH DENSITY ARRAYS FOR PROTEOME ANALYSIS AND METHODS AND COMPOSITIONS THEREFOR | Miller, Samuel (AU) | 2000-11-15 | — | — | EP | disclosed |
| US-6051549-A | POLYPEPTIDE; ANTITUMOR, ANTICANCER AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-04-18 | — | — | US | disclosed |
| WO-2000002906-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | disclosed |
| US-5985837-A | CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
| US-5965565-A | PIPERIDINES, PYRROLIDINES, AND HEXAHYDRO-1H-AZEPINES OF GIVEN FORMULA; CAN BE USED TO PROMOTE GROWTH OF LIVESTOCK AND IN HUMANS TREAT PHYSIOLOGICAL OR MEDICAL CONDITIONS CHARACTERIZED BY GRWOTH HORMONE DEFIENCY | MERCK & CO., INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999039210-A1 | HIGH DENSITY ARRAYS FOR PROTEOME ANALYSIS AND METHODS AND COMPOSITIONS THEREFOR | MILLER, SAMUEL (AU) | 1999-08-05 | — | — | WO | disclosed |
| EP-0752981-B1 | SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES AND THEIR USE AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0545991-B1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE ANDERS (SE) | 1998-12-02 | — | — | EP | disclosed |
| EP-0879244-A1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | THE UNIVERSITY OF MELBOURNE (AU) | 1998-11-25 | — | — | EP | disclosed |
| US-5817698-A | Substituted cycloalkylamine derivatives and their use as calcium channel antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-10-06 | — | — | US | disclosed |
| US-5770563-A | ANTIPROLIFERATIVE AGENTS, ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1998025897-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997021727-A1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | THE UNIVERSITY OF MELBOURNE (AU) | 1997-06-19 | — | — | WO | disclosed |
| US-5627035-A | Peptides that block human immunodeficiency virus and methods of use thereof | SYNTELLO VACCINE DEVELOPMENT AB (SE) | 1997-05-06 | — | — | US | disclosed |
| EP-0752981-A1 | SUBSTITUTED CYCLOALKYLAMINE DERIVATIVES AND THEIR USE AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026327-A1 | SUBSTITUTED CYCLOALKYLAMINE DERIVATIVES AND THEIR USE AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-05 | — | — | WO | disclosed |
| US-5346989-A | Alone or coupled to a carrier; development of synthetic aids vaccines | SYNTELLO VACCINE DEVELOPMENT KB (SE) | 1994-09-13 | — | — | US | disclosed |
| EP-0594638-A1 | PEPTIDES FOR USE IN INDUCTION OF T CELL ACTIVATION AGAINST HIV-1 | SYNTELLO VACCINE DEVELOPMENT AB (SE) | 1994-05-04 | — | — | EP | disclosed |
| EP-0545991-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE, Anders (SE) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992021377-A1 | PEPTIDES FOR USE IN INDUCTION OF T CELL ACTIVATION AGAINST HIV-1 | SYNTELLO INC. (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1992003147-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | SYNTELLO VACCIN DEVELOPMENT KB (SE) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992003147-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | SYNTELLO VACCIN DEVELOPMENT KB (SE) | 1992-03-05 | — | — | WO | disclosed |